Kalray Unveils Coolidge™ at CES 2020
6.1.2020 20:00:00 EET | Business Wire | Press release
Kalray (Paris:ALKAL), a pioneer in processors for new intelligent systems, today announced the company will showcase its MPPA-3 aka Coolidge™, its third generation of unique and patented MPPA® (Massively Parallel Processor Array) processor family at CES 2020 in Las Vegas, from January 7 to 10, 2020.
COOLIDGE™ DEMONSTRATED AT CES
Just a few weeks after having received the first samples of Coolidge from manufacturing, Kalray will showcase a complete Artificial Intelligence use case running on Coolidge at CES, including a common demo with NXP, one of the leading semiconductor companies.
Coolidge samples general availability is planned for April.
COOLIDGE UNIQUELY POSITIONED FOR THE BOOMING MARKET OF INTELLIGENT SYSTEMS
Coolidge represents a 25X performance improvement (1) over second generation MPPA, with improvement of artificial intelligence capacities, increased ease of programming and higher-performance interfaces in particular for next generation of data centers.
Coolidge is targeting the booming market of intelligent systems, from next generation of data center infrastructure, 5G to next generation of cars. Coolidge is a compelling choice versus FPGA, which are expensive and difficult to program; GPU, which are tailored for mathematical algorithms; and AI processors, designed for AI only. Coolidge-based cards can be configured to deliver specialized acceleration performance in a wide set of demanding functions such as vision, signal processing, encryption, software stacks, real-time protocols, etc.
Eric Baissus, CEO of Kalray comments: “Yet another important phase for the company. Coolidge is the platform to support company's ambitions on data center markets, answering needs of growing diversity of Data Center workload acceleration and on automotive, enabling integration of multiple critical functions on the same chip while providing huge computing performance.”
DATA CENTER’S GROWING NEED FOR ACCELERATIONS AT COMPUTE, STORAGE AND NETWORKING
“2CRSi is eager to evaluate the new Coolidge processor from Kalray and excited to explore solutions leveraging Kalray’s configurable cards. The performance of this third-generation processor will enable an expansion of our offer in high-growth areas such as Artificial Intelligence or compute acceleration, while enabling more and more distributed and disaggregated data center implementations”, said Alain Wilmouth, CEO of 2CRSi.
AUTOMOTIVE AND EMBEDDED MARKETS NEED FOR INTEGRATION OF MULTIPLE CRITICAL FUNCTIONS AND HIGH COMPUTE PERFORMANCE
“We are very happy to see the strategic partnership with Kalray reach a new milestone and have Coolidge integrated into the NXP BlueBox, our development platform for automated driving, showcased at CES. We are convinced NXP and Kalray will bring multiple benefits to the development and industrialization of ADAS and AD vehicles with safe and secure solutions integrating multiple critical functions and providing very high computing performance” said Kamal Khouri, Vice President & General Manager, Advanced Driver Assistance, NXP.
Coolidge has been designed to address the challenges and constraints of the new generation of intelligent systems:
- High computing power with low energy consumption
- Open and easily programmable system
- Real-Time data processing and deterministic behavior
- Concurrent execution of many heterogeneous critical tasks in parallel on a single chip
- Advanced security and safety mechanisms suitable for the most demanding systems, defined in collaboration with Kalray’s partners in the aerospace, defense and automotive fields
For more information and to view the demonstrations, come and visit us at CES from January 7 to 10 at Las Vegas, USA: NXP’s booth #CP18, Central Plaza.
Next publication:
January 22, 2020: H2 2019 business report
ABOUT KALRAY
Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is the pioneer in processors for new intelligent systems. A genuine technological breakthrough, “intelligent” processors are able to intelligently analyze a vast quantity of data on the fly and to make decisions and interact in real time with the outside world. These intelligent processors will be largely deployed in fast-growing sectors such as new-generation networks (intelligent data centers) and autonomous vehicles, as well as in healthcare equipment, drones and robots. Kalray’s offering spans both processors and global solutions (electronic boards and software). Created in 2008 as a spin-off of CEA (“Commissariat à l’Énergie Atomique”, the French Alternative Energies and Atomic Energy Commission), Kalray addresses a broad spectrum of customers including server manufacturers, intelligent system integrators and consumer product manufacturers such as car makers. Read more at: www.kalrayinc.com
1 25 TOPS (Tera Operations Per Second) performance for Coolidge versus 1 TOPS for previous generation Bostan
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200106005664/en/
Contact information
INVESTOR CONTACTS
Eric BAISSUS
contactinvestisseurs@kalray.eu
Tel.
+33 (0)4 76 18 90 71
ACTUS finance & communication
Caroline LESAGE
kalray@actus.fr
+
33 1 53 67 36 79
MEDIA CONTACTS
Loic HAMON
communication@kalray.eu
Tel.
+33 (0)4 76 18 90 71
ACTUS finance & communication
Serena BONI
sboni@actus.fr
Tel.
+33 (0)4 72 18 04 92
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
